• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
171026 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  ( I/ S' P% m1 Y9 \8 J3 l2 O

: T+ m( U- M, B8 n% H" A, b" w5 i& b/ W' g3 `6 t  k
Sub-category:
2 r. V& W3 x7 @Molecular Targets
% w( k: X7 W+ d- Q% D+ O; [1 `6 C- T- v+ q2 E8 i
7 N  m6 J9 E8 d: H2 y) Y
Category:% W' e+ W1 \* P! _* |1 p
Tumor Biology
" z. R' B4 ^; {* \5 s( [, I4 j# f& j& `9 J# t; }2 w* x$ E9 h

/ Y( U& P  T  C, g$ DMeeting:
' j& N% u8 i0 L, m2 C8 N1 s2011 ASCO Annual Meeting
! X+ F* h0 g  M$ \5 F. r( {5 \( F; s3 B% P, L& k' h; b( f
' B$ e1 D5 ^2 I$ u' F4 C
Session Type and Session Title:) |) e" c$ i5 l
Poster Discussion Session, Tumor Biology ' q: l7 P% ^! Q" V, G2 c0 r  `3 p/ J9 U
0 X( M3 E7 G4 A8 H( H. v8 k4 ^
& [4 a7 m4 S7 W4 G4 ~) {! z0 l0 W3 s
Abstract No:
! @- e- v/ ~4 Z$ H* w10517
) k7 e1 a8 B1 }. u* L2 i
4 D& Y5 N- h0 m5 U4 L* V( W
/ Q0 [9 X6 Z% C2 ACitation:
! k6 L: ]8 b: w1 M4 `; n+ qJ Clin Oncol 29: 2011 (suppl; abstr 10517)
9 ^9 J  r0 ]7 @' U5 v
4 h; M! i4 R  q: L9 L8 F& k  g4 q: ]; ], W0 L
Author(s):
6 `2 `# Y% r' c4 \' c8 MJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 2 e2 K( h' \, t5 q/ ~& k) l
: G& d9 s" F( G, k

# A7 r2 H- o2 M) `$ c+ h/ l% E) F# i5 ^1 L
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.  Q. L2 L; B2 \% U. l4 H4 b

5 f  i0 Q# S! VAbstract Disclosures7 l) |/ J* {, J: I" T
2 ^( N% _+ [& t0 ~# p
Abstract:% l4 _/ G9 C; [7 I) k" V4 p
: w, ~0 s; k2 L" y' q

; q! m; A8 T" d' w* _" x; aBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
: z' ]; u/ y! H  B% A
% ^5 C3 x+ e( q3 f' |1 [3 R 0 m9 k8 d& n% |
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
5 w$ T7 m/ s( h5 I没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

3 c! n* x. y+ _: s) o- v+ Q化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 7 \! W3 X3 ]! K/ k8 |
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。+ a8 z- B6 z, {/ X1 x  ^
ALK一个指标医院要900多 ...

5 B  N$ o  h$ L. F- V/ p2 C3 a平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
3 Y/ |2 H' R1 W! S. E$ J
3 C  e5 p- f- s4 X现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表